TickerFacts.

A business in context

AZN research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-07 · 8010 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 6-K · Current report

    Report date 2026-09-01 · 0001654954-26-008042

  2. 6-K · Current report

    Report date 2026-09-01 · 0001654954-26-008040

  3. 6-K · Current report

    Report date 2026-09-01 · 0001654954-26-007992

  4. 6-K · Current report

    Report date 2026-09-01 · 0001654954-26-007990

  5. 6-K · Current report

    Report date 2026-09-01 · 0001654954-26-007988

  6. 6-K · Current report

    Report date 2026-09-01 · 0001654954-26-007986

  7. 6-K · Current report

    Report date 2026-09-01 · 0001654954-26-007983

  8. 6-K · Current report

    Report date 2026-08-27 · 0001654954-26-007894

  9. 6-K · Current report

    Report date 2026-08-25 · 0001654954-26-007840

  10. 6-K · Current report

    Report date 2026-08-19 · 0001654954-26-007742

  11. 6-K · Current report

    Report date 2026-08-17 · 0001654954-26-007681

  12. 6-K · Current report

    Report date 2026-08-17 · 0001654954-26-007679

  13. 6-K · Current report

    Report date 2026-08-17 · 0001654954-26-007677

  14. 4 · Ownership change

    Report date 2026-08-06 · 0002122411-26-000001

  15. 6-K · Current report

    Report date 2026-08-03 · 0001654954-26-007169

  16. 6-K · Current report

    Report date 2026-08-03 · 0001654954-26-007166

  17. 6-K · Current report

    Report date 2026-07-31 · 0001654954-26-007050

  18. 6-K · Current report

    Report date 2026-07-27 · 0001654954-26-006897

  19. 6-K · Current report

    Report date 2026-07-27 · 0001654954-26-006895

  20. 6-K · Current report

    Report date 2026-06-30 · 0001104659-26-086846

  21. 6-K · Current report

    Report date 2026-07-23 · 0001654954-26-006803

  22. 6-K · Current report

    Report date 2026-07-14 · 0001654954-26-006637

  23. 6-K · Current report

    Report date 2026-07-09 · 0001654954-26-006554

  24. 4 · Ownership change

    Report date 2026-07-06 · 0001104659-26-081807

  25. 6-K · Current report

    Report date 2026-07-01 · 0001654954-26-006430

  26. 6-K · Current report

    Report date 2026-07-01 · 0001654954-26-006427

  27. 6-K · Current report

    Report date 2026-06-29 · 0001654954-26-006251

  28. 6-K · Current report

    Report date 2026-06-29 · 0001654954-26-006239

  29. 4 · Ownership change

    Report date 2026-06-08 · 0001104659-26-074570

  30. 6-K · Current report

    Report date 2026-06-15 · 0001654954-26-005964

  31. 6-K · Current report

    Report date 2026-06-01 · 0001654954-26-005587

  32. 6-K · Current report

    Report date 2026-06-01 · 0001654954-26-005586

  33. 6-K · Current report

    Report date 2026-05-29 · 0001654954-26-005498

  34. 6-K · Current report

    Report date 2026-05-27 · 0001654954-26-005381

  35. 6-K · Current report

    Report date 2026-05-26 · 0001654954-26-005309

  36. 4 · Ownership change

    Report date 2026-05-20 · 0001104659-26-065693

  37. 4 · Ownership change

    Report date 2026-04-07 · 0001104659-26-057906

  38. 4 · Ownership change

    Report date 2021-03-15 · 0001104659-21-036719

  39. 4 · Ownership change

    Report date 2019-12-19 · 0001104659-20-012390

  40. 4 · Ownership change

    Report date 2019-10-07 · 0000899243-19-025369

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 1 transaction rows1SGrant / award: 3 transaction rows3AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

4 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-08
2026-06-16
Sharma ManiA · Grant / award
Acquired
Ordinary Shares1.0179.75
2026-05-20
2026-05-22
Sharma ManiS · Sale
Disposed
Ordinary Shares11893.0185.78
2026-05-06
2026-05-08
Sharma ManiA · Grant / award
Acquired
Ordinary Shares1.0186.28
2026-04-07
2026-05-08
Sharma ManiA · Grant / award
Acquired
Ordinary Shares1.0196.03

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0000901832ASTRAZENECA PLC
AstraZenecaAstraZeneca CanadaAstraZeneca PTYAstraZeneca KoreaAstraZeneca ABAstraZeneca IndiaAstraZeneca OyAstraZeneca Farmaceutica Spain S.A.AstraZeneca Czech Republic s.r.o.Cambridge Antibody TechnologyAstraZeneca (United States)Amylin PharmaceuticalsAcerta Pharma

Showing 13 of 13 imported Wikidata subsidiary claims. Additional aliases appear below.

No parent relationship is available in this import; this is not proof of independence.

Legal Entity Identifier
PY6ZZQWO2IZFZC3IOL08
GLEIF legal name
ASTRAZENECA PLC
Entity / LEI registration status
ACTIVE / ISSUED
Reference data updated
2026-07-29T13:42:39Z

direct-parent: no parent LEI supplied

ultimate-parent: no parent LEI supplied

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • AstraZeneca · subsidiary · wikidata
  • AZ · alias · wikidata
  • AstraZeneca Canada · subsidiary · wikidata
  • AstraZeneca Canada Inc. · subsidiary · wikidata
  • AstraZeneca PTY · subsidiary · wikidata
  • AstraZeneca PTY Ltd · subsidiary · wikidata
  • AstraZeneca Korea · subsidiary · wikidata
  • AstraZeneca Korea Co. Ltd · subsidiary · wikidata
  • AstraZeneca AB · subsidiary · wikidata
  • AstraZeneca Sweden · subsidiary · wikidata
  • AstraZeneca India · subsidiary · wikidata
  • AstraZeneca India Private Limited · subsidiary · wikidata
  • AstraZeneca Oy · subsidiary · wikidata
  • Astra Zeneca Oy · subsidiary · wikidata
  • AstraZeneca K.K. · subsidiary · wikidata
  • AstraZeneca Farmaceutica Spain S.A. · subsidiary · wikidata
  • AstraZeneca Farmacéutica Spain, S.A. · subsidiary · wikidata
  • AstraZeneca Czech Republic s.r.o. · subsidiary · wikidata
  • AstraZeneca Czech Republic SRO · subsidiary · wikidata
  • Cambridge Antibody Technology · subsidiary · wikidata
  • Cambridge Antibody Technology Group Plc · subsidiary · wikidata
  • CAT · subsidiary · wikidata
  • AstraZeneca (United States) · subsidiary · wikidata
  • MedImmune Inc. · subsidiary · wikidata
  • Molecular Vaccines, Inc. · subsidiary · wikidata
  • MedImmune · subsidiary · wikidata
  • Amylin Pharmaceuticals · subsidiary · wikidata
  • Acerta Pharma · subsidiary · wikidata
  • ZENECA GROUP PLC · former SEC name · 1995-03-13 to 1999-02-05
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

No USD annual revenue periods with complete CPI coverage are available. Non-USD statements are not converted with U.S. CPI.

Bureau of Labor Statistics · retrieved 2026-09-07 · 9 selected series; gaps remain missing

Explore the CPI history ↗